Call us 24/7

Clinical trials

Search our clinical trials

Cancer Treatment Centers of America® (CTCA) is committed to providing new and innovative treatments for our cancer patients whenever possible. This includes enrolling qualified patients in carefully selected clinical trials for cancer. Cancer clinical trials are a key testing ground for determining the effectiveness and safety of new treatments and drugs for cancer and other diseases. Our doctors may recommend that cancer patients enroll in cancer clinical trials if they meet specific criteria. Cancer trials may offer patients access to treatment options that would otherwise be unavailable to them. Talk to your doctor about whether a cancer trial is a good option for you and ask about the risks and various requirements involved. Use the tool below to find a CTCA® clinical trial for your cancer type.

Filters

5 Clinical Trials

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

The purpose of this open-label study is to determine the effects of TGR-1202 in patients with relapsed or refractory follicular lymphoma.

The purpose of this study is to evaluate whether copanlisib in combination with rituximab is superior to a placebo in combination with rituximab in prolonging progression free survival in some patients with relapsed indolent non-Hodgkin lymphoma.

The TAPUR study is a clinical trial that aims to improve our understanding of how commercially available anti-cancer drugs perform on a broader range of cancers, by matching the drugs to tumors with specific genomic mutations that the drugs are designed to target.

This is a single arm study to evaluate the efficacy, safety and tolerability of zanubrutinib (BGB-3111) in patients with relapsed/refractory marginal zone lymphoma.

The primary objectives will be to determine the efficacy of MT-3724 as monotherapy in subjects with relapsed or refractory DLBCL based on the overall response rate (ORR) by the revised Lugano Classification for lymphoma adjusted according to lymphoma response to immunomodulatory therapy criteria (LYRIC) hereinafter referred to as “revised Lugano Criteria” (Cheson et al, 2014, 2016).